Cambodia Hep-C
Worldwide, an estimated 71 million people are infected with the hepatitis C virus, double the number living with HIV.

While hepatitis C can be cured, few people have access to treatment.

A blood-borne virus that attacks the liver, hepatitis C kills nearly 400,000 people each year, mostly from resulting complications, usually cirrhosis or liver cancer.

While hepatitis C is found worldwide, the vast majority of people with the disease live in developing countries; China, India, Egypt and Indonesia are particularly affected.

Hepatitis C is a curable disease, but millions don't have access to treatment due to high prices.

Website

MSF Access Campaign

msfaccess.org

Quick facts

When Big Pharma plays for keeps, who wins and who loses? (ENG)

When Big Pharma plays for keeps, who wins and who loses? (ENG)

When Big Pharma plays for keeps, who wins and who loses?

In this , we follow the development of sofosbuvir, a true breakthrough drug for hepatitis C, a severe virus that attacks the liver and can be deadly.

The story of sofosbuvir illustrates how research and development for new prescription drugs really works.

After a scientist who got millions in tax-dollars started a small company that did the long work of discovering a new medicine, and showed that it was safe and effective, a giant corporation bought up the next big blockbuster drug and cashed in.

As the new owner of sofosbuvir, Gilead continued clinical trials to learn more about the drug’s effectiveness, safety, side-effects and dosage before seeking government approval to bring the new drug to market.

Gilead first set the price for sofosbuvir at $1000 per pill. That made its worth per gram 67 times greater than gold, but research shows that it only costs $42 to produce.

 
Essential Hepatitis C medicine Sofosbuvir and Daclatasvir
Hepatitis C

Appeal lodged against decision to uphold Gilead’s patent on hepatitis C drug

Press Release 5 Dec 2018
 
Out of Darkness- fighting Hepatitis C
Ukraine

"I am one of you: I live with HIV and used to live with hepatitis C"

Voices from the Field 30 Nov 2018
 
Out of Darkness- fighting Hepatitis C
Ukraine

Mykolaiv project shows that hepatitis C can be effectively treated in people living with HIV

Project Update 30 Nov 2018
 
Out of Darkness- fighting Hepatitis C
Hepatitis C

MSF calls for end to Gilead’s hepatitis C drug monopoly

Press Release 11 Sep 2018
 
Out of Darkness- fighting Hepatitis C
Photo Story

Out of Darkness: Fighting Hepatitis C in Ukraine

27 Jul 2018
Photo Story
 
Free Hepatitis clinic in Meerut
Photo Story

One year, 1,198 patients

2 Mar 2018
Photo Story
 
Cambodia Hep-C
Access to medicines

MSF challenges Gilead’s patent application for hepatitis C treatment

Press Release 15 Dec 2017
 
Mykolaiv Project
Ukraine

People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

Press Release 1 Dec 2017
 
Cambodia Hep-C
Hepatitis C

MSF secures lower price for generic hepatitis C treatment

Press Release 31 Oct 2017
Advanced HIV management in Homa Bay
Medical Resource

MSF Field Research

We produce important research based on our field experience. So far, we have published articles in over 100 peer-reviewed journals. These articles have often changed clinical practice and have been used for humanitarian advocacy. All of these articles can be found on our dedicated Field Research website.